J.P. Morgan analyst Robbie Marcus maintained a Buy rating on Boston Scientific today and set a price target of $100.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Robbie Marcus has given his Buy rating due to a combination of factors that emphasize Boston Scientific’s durable growth profile and attractive valuation. He notes that the company is positioned across several medical categories that are expanding at a mid-single-digit or better pace, supporting above-market revenue growth even after the recent reset to electrophysiology expectations.
He also highlights the sizable and still rapidly growing EP opportunity, the continued strong trajectory of WATCHMAN, and a deep pipeline supported by disciplined bolt-on acquisitions that together underpin confidence in acceleration beyond 2026. On valuation, his $100 December 2026 price objective implies roughly 25x projected 2027 cash EPS, which he sees as justified given Boston Scientific’s faster growth versus large-cap peers and conservative assumptions that still leave a skew toward upside risk.
In another report released on February 5, Evercore ISI also maintained a Buy rating on the stock with a $96.00 price target.